Clinical Trial: Breast Cancer, Cancer

NRG-BR004

Full Name

A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

Description

Subjects will be scanned on the QT Ultrasound Breast Scanner. For subjects that may have breast calcifications and/or mass(es) and/or other finding(s) on the QT scan image(s), standard imaging modalities (e.g., mammogram and HHUS) will be performed per ACR recommendations. If available, subjects may provide copies of their breast imaging exams and related reports. Demographics and medical history will be collected.

Eligibility

Inclusion Criteria
  • At least 18 years old
  • Willing and able to provide written, signed informed consent
  • Willing and able to comply with all study procedures
Exclusion Criteria
  • Inability to tolerate the scan
  • Present infection risk
  • Allergies to device materials
  • Inability to successfully "fit" breast into the investigational device
  • Currently pregnant as reported by the subject
  • Body weight greater than 400 lbs. (180 kg)
  • Any other conditions that the Investigator determines to interfere with the conduct of the study or evaluation of results
Doctor(s) Running This Study

Specialties

  • Hematology/Medical Oncology

Area of focus i

  • Gastrointestinal cancer
  • Colorectal Cancer (Colon Cancer and Rectal Cancer)
  • Genitourinary cancer

Affiliated with

LVPG Cliniciani

Accepting New Patients